Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095208 | 0.92 | KMT2A (0.44) | AKR1C3KMT2AUSP2MAPTCHKA | |
| SCHEMBL31252540 | 0.83 | AKR1C3 (0.57) | AKR1C3KMT2AUSP2MAPTIGF1R | |
| SCHEMBL23705658 | 0.78 | KMT2A (0.53) | AKR1C3KMT2AUSP2MAPTCHKA | |
| SCHEMBL382079 | 0.78 | KMT2A (0.58) | AKR1C3KMT2AUSP2MAPTCHKA | |
| SCHEMBL220360 | 0.77 | HTR3E (0.57) | AKR1C3KMT2AMAPTALDH1A1GAA | |
| SCHEMBL662317 | 0.77 | MAPT (0.52) | KMT2AMAPTALDH1A1GAAMEN1 | |
| SCHEMBL216663 | 0.77 | ALDH1A1 (0.57) | KMT2AMAPTALDH1A1GAAMEN1 | |
| SCHEMBL7513534 | 0.77 | LTA4H (0.47) | AKR1C3KMT2AUSP2MAPTCHKA | |
| SCHEMBL240624 | 0.77 | ADRB1 (0.57) | AKR1C3KMT2AUSP2MAPTALDH1A1 | |
| SCHEMBL2703274 | 0.76 | ALDH1A1 (0.58) | AKR1C3KMT2AUSP2MAPTCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105294557-A | Preparation and application of 7-hydroxy-6-arylcarbonylquinolinone compounds | UNIV SHENYANG PHARMACEUTICAL | 2016-02-03 | — | — | CN | claimed |
| CN-105237474-A | Preparation method and application of 6-hydroxy-7-arylformylquinolinone compounds | UNIV SHENYANG PHARMACEUTICAL | 2016-01-13 | — | — | CN | claimed |
| CN-105294557-A | Preparation and application of 7-hydroxy-6-arylcarbonylquinolinone compounds | UNIV SHENYANG PHARMACEUTICAL | 2016-02-03 | — | — | CN | disclosed |
| CN-105237474-A | Preparation method and application of 6-hydroxy-7-arylformylquinolinone compounds | UNIV SHENYANG PHARMACEUTICAL | 2016-01-13 | — | — | CN | disclosed |
| EP-2489660-A1 | Methods for making central nervous system agents that are TRPV1 antagonists | Abbott Laboratories (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| US-8232411-B2 | Methods for making central nervous system agents that are TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| CN-102036969-A | Methods for making central nervous system agents that are TRPV1 antagonists | ABBOTT LAB | 2011-04-27 | — | — | CN | disclosed |
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008146063-A1 | NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT6 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársagág (HU) | 2008-12-04 | — | — | WO | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
| US-5081112-A | Administering an aryl phosphonate carboxamide | OTSUKA PHARMACEUTICAL FACTORY INC. (JP) | 1992-01-14 | — | — | US | disclosed |
| US-5055474-A | Antihypoxia, hypotensive, antiinflammatory agents; anoxia treatment | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-08 | — | — | US | disclosed |
| EP-0173331-B1 | 2,3-DIHYDRO-1H-INDENE DERIVATIVES, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4895847-A | ANTIHYPOXIC, ANTIINFLAMMATORY, HYPOTENSIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-01-23 | — | — | US | disclosed |
| US-4822780-A | CALCIUM ANTAGONIST, ANTIINFLAMMATORY AGENT | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1989-04-18 | — | — | US | disclosed |
| US-4788130-A | ANTIHYDOXIC, HYPOTENSIVE, ANTIINFLAMMATORY AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-29 | — | — | US | disclosed |
| EP-0173331-A2 | 2,3-Dihydro-1H-indene derivatives, a process for preparing them and pharmaceutical compositions containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | TRPV1, TRPV2, OPRL1 | AKR1C3 607/4885KMT2A 3745/4885USP2 1149/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | AKR1C3 843/4885KMT2A 2802/4885USP2 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.